You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 8,282,914

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,282,914

Title:	Method for treating atherosclerosis by administering human MCP1 fusions
Abstract:	The present invention provides polypeptides including MCP1 fused, optionally, by a linker, to an immunoglobulin. Methods for using the polypeptides to treat medical disorders are also covered.
Inventor(s):	Chou; Chuan-Chu (Westfield, NJ), Bober; Loretta A. (Linden, NJ), Sullivan; Lee (Somerset, NJ)
Assignee:	Merck, Sharp & Dohme Corp. (Rahway, NJ)
Application Number:	13/098,641
Patent Claims:	1. A method for impeding migration of CCR2-bearing cells into inflammatory tissue, in a subject with atherosclerosis, comprising administering, to the subject, a therapeutically effective amount of an isolated polypeptide comprising a human MCPI polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 2 fused to a human immunoglobulin gamma-1 polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 7. 2. The method of claim 1 wherein the polypeptide comprising the human MCP1 polypeptide and the human immunoglobulin gamma-1 polypeptide comprises one human MCP1 polypeptide fused to one human immunoglobulin gamma-1 polypeptide. 3. The method of claim 2 wherein the polypeptides are fused by a peptide linker. 4. The method of claim 1 wherein the polypeptide comprising the human MCP1 polypeptide and the human immunoglobulin gamma-1 polypeptide is in a pharmaceutical composition comprising a pharmaceutically acceptable carrier. 5. The method of claim 1 wherein the polypeptide comprising the human MCP1 polypeptide and the immunoglobulin gamma-1 polypeptide is administered to the subject in association with one or more further therapeutic agents. 6. The method of claim 5 wherein the further therapeutic agent is a member selected from the group consisting of valdecoxib; triamcinolone acetonide; tolmetin; tiaprofenic acid; tenoxicam; tazarotene; sulindac; sulfasalazine; salicylic acid; rofecoxib; prednicarbate; piroxicam, salsalate; phenylbutazone; petroleum jelly; penicillamine; oxaprozin; oilated oatmeal; naproxen; nabumetone; mycophenolate mofetil; mometasone furoate; metronidazole; methotrexate; mesalamine; meloxicam; mefenamic acid; meclofenamate; lumiracoxib; ketorolac; ketoprofen; isotretinoin; injectable gold; infliximab; indomethacin; ibuprofen; hydroxyurea; hydroxychloroquine; hydrocortisone; halobetasol propionate; halcinonide; gold sodium thiomalate; fluticasone propionate; flurbiprofen; flurandrenolide; fluocinonide; fluocinolone acetonide; floctafenine; fenoprofen; etoricoxib; etodolac; etanercept; epsom salts; efalizumab; diflunisal; diflorasone diacetate; diclofenac; desoximetasone; desonide; Dead Sea salts; cyclosporine; coal tar; clobetasol propionate; ciprofloxacin; chloroquine; celecoxib; calcipotriene; budesonide; betamethasone valerate; betamethasone dipropionate; betamethasone benzoate; azathioprine; aurothioglucose; auranofin; aspirin; anthralin; anakinra; amcinonide; aloe vera; alefacept; alclometasone dipropionate; adalimumab; acitretin; ABX-IL8; a mixture of hydrocortisone, dexamethasone, methylprednisolone and prednisolone; a dietary vitamin B12 supplement; a dietary folate supplement; a dietary calcium supplement; 6-Thioguanine; and 6-mercaptopurine. 7. The method of claim 1 wherein the polypeptide comprising the human MCP1 polypeptide and the human immunoglobulin gamma-1 polypeptide is administered in association with a non-steroidal anti-inflammatory drug or a COX-2 inhibitor.

Details for Patent 8,282,914

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998	⤷ Try a Trial	2025-08-12
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998	⤷ Try a Trial	2025-08-12
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999	⤷ Try a Trial	2025-08-12
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004	⤷ Try a Trial	2025-08-12
Immunex Corporation	ENBREL	etanercept	Injection	103795	02/01/2007	⤷ Try a Trial	2025-08-12
Immunex Corporation	ENBREL MINI	etanercept	Injection	103795	09/14/2017	⤷ Try a Trial	2025-08-12
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.